Examples of using Mean changes in English and their translations into Greek
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Financial
-
Official/political
-
Computer
There were no statistically significant differences in the mean changes in weight, height,
Mean changes at week 48(end of double-blind phase)
where mean changes from baseline in QTcF(Fridericia's correction)
The mean changes in body weight from double-blind baseline to double-blind end point were +0.94 kg
Mean changes at week 48(end of double-blind phase)
Mean changes at week 48(end of randomised phase)
Mean changes in mammographic breast density in the bazedoxifene 20 mg group were significantly reduced from baseline(-1.45 percentage points,
At Week 52, adjusted mean changes from baseline in HbA1c relative to placebo were -0.33% and -0.20% for patients treated with dapagliflozin 5 mg, in the two studies, respectively.
The adjusted mean changes from baseline in HbA1c for the dapagliflozin
The mean changes from baseline in sitting blood pressure were greatest at 1 hour, -9.1 mmHg(SD± 12.5) and -3.0(SD± 4.9) mmHg for systolic
The number of active joints was significantly reduced compared to baseline in patients receiving tocilizumab compared to placebo(adjusted mean changes of -14.3 vs -11.4, p=0.0435).
add-on therapy to metformin, pioglitazone, or metformin plus a sulfonylurea resulted in mean changes from baseline in.
the parenteral nutrition calories consumption continued to decrease with percentage mean changes from baseline of -39.15%(±39.08)
Mean changes at week 48(end of randomised phase)
Mean changes at week 48(end of randomised phase)
Mean changes at week 48(end of double blind phase)
At months 3 and 6 of treatment in the phase III clinical study in patients with SPMS, mean changes from baseline in FEV1 in the siponimod group were -0.1 L at each time point,
At Week 52, the adjusted mean changes in body weight from baseline for dapagliflozin 5 mg relative to placebo were -2.56 kg
The adjusted mean changes for dapagliflozin 5 mg relative to placebo in the mean amplitude of glucose excursion from baseline to Week 24 were -0.96 mmol/L(-17.30 mg/dL)
At week 52, adjusted mean changes from baseline in HbA1c in the saxagliptin